ライフサイエンスコーパス: obliterans

1 t of interstitial fibrosis and bronchiolitis obliterans.

2 opathic pneumonia syndrome and bronchiolitis obliterans.

3 nt might be an option to treat bronchiolitis obliterans.

4 the condition is often called bronchiolitis obliterans.

5 ome the challenge presented by bronchiolitis obliterans.

6 angiographically involved in thromboangiitis obliterans.

7 irway obstruction arising from bronchiolitis obliterans.

8 rcome in long-term survival is bronchiolitis obliterans.

9 t were reported to have severe bronchiolitis obliterans.

10 manifesting as scleroderma and bronchiolitis obliterans.

11 cute rejection; none developed bronchiolitis obliterans.

12 dysfunction characteristic of bronchiolitis obliterans.

13 mmon causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61, 21%), and pos

14 ival was 77% for patients with bronchiolitis obliterans, 37% for patients with IPS, and 36% for patie

15 s (obliterative bronchiolitis, bronchiolitis obliterans), acute bronchiolitis, diffuse panbronchiolit

16 d accuracy in diagnosing early bronchiolitis obliterans after lung transplantation.

17 ciated with the development of bronchiolitis obliterans after transplantation, we determined whether

18 y a role in the development of bronchiolitis obliterans after transplantation.

19 Asthma as well as bronchiolitis obliterans and chronic bronchitis are chronic lung disea

20 eatures distinguishing it from bronchiolitis obliterans and idiopathic pulmonary fibrosis.

21 stic fibrosis, post-transplant bronchiolitis obliterans and more recently chronic obstructive pulmona

22 ociations between diacetyl and bronchiolitis obliterans and other severe respiratory diseases observe

23 uent disease, earlier onset of bronchiolitis obliterans and shorter survival.

24 ht be helpful to better manage bronchiolitis obliterans and to detect and treat it earlier.

25 however, including infections, bronchiolitis obliterans, and complications of immunosuppression remai

26 atients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung transplant.

27 c pneumonia syndrome (IPS) and bronchiolitis obliterans are now recognized as part of a spectrum of p

28 of patients with fibrosis and bronchiolitis obliterans, at each successive scheduled surveillance ti

29 and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectively, for which

30 Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, we used an esta

31 Bronchiolitis obliterans (BO) is a detrimental late pulmonary complica

32 Bronchiolitis obliterans (BO) is the pathologic manifestation of chron

33 of lung transplantation, with bronchiolitis obliterans (BO) representing the predominant pathologica

34 The pathogenesis of bronchiolitis obliterans (BO), a common and devastating obliterative d

35 graft survival, occurrence of bronchiolitis obliterans (BO), and episodes of rejection.

36 y obliteration, which leads to bronchiolitis obliterans (BO), which is pathognomonic for cGVHD of the

37 ymphocytic bronchitis (LB) and bronchiolitis obliterans (BO).

38 system cGVHD model that induces bronchiolar obliterans (BO).

39 viremia increases the risk of bronchiolitis obliterans (BOS) or death and retransplantation in the f

40 traluminal fibrotic lesions of bronchiolitis obliterans by day 28.

41 they probably had occupational bronchiolitis obliterans caused by the inhalation of volatile butter-f

42 on and with the development of bronchiolitis obliterans could not be confirmed in human lung allograf

43 Bronchiolitis obliterans developed in 29% of patients with a BALT-posi

44 hat results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD.

45 tion course was complicated by bronchiolitis obliterans from chronic rejection and by recent pulmonar

46 se; in contrast, patients with bronchiolitis obliterans from Stevens-Johnson syndrome often have prog

47 Patients with postinfectious bronchiolitis obliterans generally have chronic, nonprogressive diseas

48 ith histopathologically proved bronchiolitis obliterans (group A) and 21 with normal biopsy findings

49 Experimental models of IPS and bronchiolitis obliterans have proven useful to test strategies designe

50 ied to show histopathology for bronchiolitis obliterans in all allogeneic grafts.

51 The diagnosis of bronchiolitis obliterans in children can be made with confidence based

52 sis, treatment, and outcome of bronchiolitis obliterans in the nontransplant, pediatric population.

53 cidence of acute rejection and bronchiolitis obliterans in younger versus older children may reveal i

54 Thromboangiitis obliterans is a nonatherosclerotic segmental inflammator

55 ifferent cGVHD model, in which bronchiolitis obliterans is a prominent manifestation, F4/80+ macropha

56 Bronchiolitis obliterans is a rare form of chronic obstructive lung di

57 st disease (GVHD) and IPS, and bronchiolitis obliterans is pathognomonic of chronic GVHD.

58 udying rare diseases such as thromboangiitis obliterans is that there are no significant research dol

59 Bronchiolitis obliterans is the leading cause of chronic graft failure

60 ary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n =

61 me (n=4), hemosiderosis (n=1), bronchiolitis obliterans (n=1), sarcoidosis (n=1), and bronchiectasis

62 monary vascular disease (n=6), bronchiolitis obliterans (n=2), bronchopulmonary dysplasia (n=1), graf

63 neumonia syndrome (IPS, n=19), bronchiolitis obliterans (n=22), and other uncommon syndromes (n=5).

64 Bronchiolitis obliterans organizing pneumonia (BOOP) and acute respira

65 The peak prevalence of bronchiolitis obliterans organizing pneumonia (BOOP) and interstitial

66 Bronchiolitis obliterans organizing pneumonia (BOOP) has been reported

67 se alveolar damage (DAD) in 2, bronchiolitis obliterans organizing pneumonia (BOOP) in 1, and usual i

68 Bronchiolitis obliterans organizing pneumonia (BOOP) is a clinical syn

69 Bronchiolitis obliterans organizing pneumonia (BOOP) is a term that wa

70 neumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), and others.

71 hin air spaces consistent with bronchiolitis obliterans organizing pneumonia (BOOP).

72 obliterans syndrome (BOS), and bronchiolitis obliterans organizing pneumonia (BOOP).

73 ory distress syndrome (n = 2), bronchiolitis obliterans organizing pneumonia (n = 2), pulmonary embol

74 is, oral herpetic lesions, and bronchiolitis obliterans organizing pneumonia after 2 episodes of bact

75 Bronchiolitis obliterans organizing pneumonia and erythema nodosum are

76 e case of a lady who developed bronchiolitis obliterans organizing pneumonia and erythema nodosum sim

77 ganizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia), and pulmonary Langerha

78 ic interstitial pneumonitis, bronchoalveolar obliterans organizing pneumonia, focal fibrosis, pulmona

79 pneumonia, and the seventh had bronchiolitis obliterans organizing pneumonia.

80 The pathomechanism of bronchiolitis obliterans remains unclear and it remains a fatal compli

81 within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.6 [0.6-17.1] p

82 T studies in six patients with bronchiolitis obliterans syndrome (age range, 2 months to 5 1/2 years)

83 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic

84 are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic

85 Bronchiolitis obliterans syndrome (BOS) after lung transplantation (LT

86 orphisms on the development of bronchiolitis obliterans syndrome (BOS) after lung transplantation.

87 ng log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft survival were compar

88 nally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follow up of heart-

89 raft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttransplant survi

90 Freedom from bronchiolitis obliterans syndrome (BOS) at three years was similar in

91 Development of bronchiolitis obliterans syndrome (BOS) following lung transplantation

92 an system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine model, we hypothes

93 n on survival and the onset of bronchiolitis obliterans syndrome (BOS) in consecutive lung transplant

94 associated with development of bronchiolitis obliterans syndrome (BOS) in human lung allografts.

95 ansplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients, primarily a

96 ansplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients, primarily a

97 The term bronchiolitis obliterans syndrome (BOS) is a clinical surrogate for th

98 Bronchiolitis obliterans syndrome (BOS) is a condition of progressive

99 Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding p

100 ograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading cause of late d

101 Bronchiolitis obliterans syndrome (BOS) is the major limitation to sur

102 Bronchiolitis obliterans syndrome (BOS) is the major limitation to sur

103 Bronchiolitis obliterans syndrome (BOS) is the major obstacle to long-

104 Bronchiolitis obliterans syndrome (BOS) is the most common cause of mo

105 Bronchiolitis obliterans syndrome (BOS) is the primary limiting factor

106 function (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndr

107 elopment of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major limiting factors

108 Bronchiolitis obliterans syndrome (BOS) remains the leading obstacle t

109 Bronchiolitis obliterans syndrome (BOS) remains the main cause of graf

110 of the allograft airway during bronchiolitis obliterans syndrome (BOS) that occurs after lung transpl

111 Bronchiolitis obliterans syndrome (BOS), a condition of irreversible s

112 ung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition previously regard

113 nfectious complications and by bronchiolitis obliterans syndrome (BOS), a form of chronic rejection l

114 Bronchiolitis obliterans syndrome (BOS), a process of fibro-obliterati

115 thic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolitis obliterans

116 ic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarker can currentl

117 CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect of pseudomonas

118 ransplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the dominant chall

119 ve airflow obstruction, termed bronchiolitis obliterans syndrome (BOS), is the major cause of poor ou

120 raft rejection, represented by bronchiolitis obliterans syndrome (BOS), is the single most important

121 orders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and graft loss for

122 Bronchiolitis obliterans syndrome (BOS), pathognomonic for chronic gra

123 Bronchiolitis obliterans syndrome (BOS), the clinical correlate of chr

124 Bronchiolitis obliterans syndrome (BOS), the major cause of death on l

125 literative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized that the type

126 phy morphology, mortality, and bronchiolitis obliterans syndrome (BOS)-free survival were analyzed up

127 ften due to the development of bronchiolitis obliterans syndrome (BOS).

128 limited by the development of bronchiolitis obliterans syndrome (BOS).

129 fection) (NORMAL POST) or with bronchiolitis obliterans syndrome (BOS).

130 mary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

131 r lung transplantation (LT) is bronchiolitis obliterans syndrome (BOS).

132 ortant role in the etiology of bronchiolitis obliterans syndrome (BOS).

133 elated with the development of bronchiolitis obliterans syndrome (BOS).

134 ecline in lung function termed bronchiolitis obliterans syndrome (BOS).

135 y contribute to development of bronchiolitis obliterans syndrome (BOS).

136 ronic allograft failure termed bronchiolitis obliterans syndrome (BOS).

137 of chronic rejection, known as bronchiolitis obliterans syndrome (BOS).

138 ury would increase the risk of bronchiolitis obliterans syndrome (BOS).

139 an established risk factor for bronchiolitis obliterans syndrome (BOS).

140 ol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Everolimus group

141 outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of acute rejection.

142 in obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS), which severely limits surv

143 09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observed in the Celsi

144 nor a subsequent diagnosis of bronchiolitis obliterans syndrome (P=0.70).

145 r causes (currently defined as bronchiolitis obliterans syndrome [BOS]) is considered to reflect the

146 ts may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictive lung functio

147 iagnosis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) was made in 191 patients (42.

148 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS-restrictive a

149 nfants and young children with bronchiolitis obliterans syndrome after lung transplantation are more

150 f multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismatch model of sc

151 investigate the development of bronchiolitis obliterans syndrome and graft loss after LTX in relation

152 graft rejection in the form of bronchiolitis obliterans syndrome and its histopathologic correlate, o

153 se current literature suggests bronchiolitis obliterans syndrome and restrictive allograft syndrome a

154 urrent diagnostic criteria for bronchiolitis obliterans syndrome and reviews the epidemiology, pathog

155 plant recipients who developed bronchiolitis obliterans syndrome and were compared to stable controls

156 Emphysema, female gender, and bronchiolitis obliterans syndrome are risk factors for severe HGG.

157 ted that the increased risk of bronchiolitis obliterans syndrome associated with primary graft dysfun

158 ints were overall survival and bronchiolitis obliterans syndrome at 2 years.

159 predisposed to development of bronchiolitis obliterans syndrome but particularly to restrictive allo

160 rvival and an earlier onset of bronchiolitis obliterans syndrome compared with patients in the transp

161 tial new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomized placebo co

162 This resembles bronchiolitis obliterans syndrome developed following human lung trans

163 r clinical variables including bronchiolitis obliterans syndrome did not change this relationship.

164 sease affects the lung tissue, bronchiolitis obliterans syndrome ensues.

165 wever, toward reduced onset of bronchiolitis obliterans syndrome grade 2 or 3 was observed in TLR4 he

166 multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV1% predicted (

167 Patients with bronchiolitis obliterans syndrome had a higher risk of severe HGG than

168 Bronchiolitis obliterans syndrome has been associated with increased m

169 roblasts in the development of bronchiolitis obliterans syndrome has not been evaluated.

170 ansplantation, and potentially bronchiolitis obliterans syndrome in lung transplant recipients, with

171 de therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant recipients.

172 gress of medical management of bronchiolitis obliterans syndrome include difficulties and delays in d

173 ated with an increased risk of bronchiolitis obliterans syndrome independent of acute rejection, lymp

174 Bronchiolitis obliterans syndrome is a fibrotic occlusion of distal ai

175 Bronchiolitis obliterans syndrome is a major problem for medium-to-lon

176 Bronchiolitis obliterans syndrome is caused by a fibroproliferative pr

177 Bronchiolitis obliterans syndrome is characterized by fibrotic obliter

178 Bronchiolitis obliterans syndrome is the leading cause of chronic lung

179 ed into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), early CLAD (BOS 0p

180 Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of HSCT recipien

181 graft dysfunction manifests as bronchiolitis obliterans syndrome or the recently described restrictiv

182 factor for the development of bronchiolitis obliterans syndrome or worse overall survival.

183 Bronchiolitis obliterans syndrome remains the leading cause of morbidi

184 spiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-dependent inju

185 he remaining four patients had bronchiolitis obliterans syndrome scores of 0 compared with 5 of 13 co

186 ignificantly increased risk of bronchiolitis obliterans syndrome stage 1 (grade 1: relative risk [RR]

187 n, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage 1, using univariable and multi

188 Freedom from bronchiolitis obliterans syndrome was lower, and mortality was higher

189 n of bronchial dilatation with bronchiolitis obliterans syndrome was significant (P = .02).

190 atients with clinically proved bronchiolitis obliterans syndrome were mosaic perfusion in five (83%)

191 Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstacle to long-ter

192 onic lung allograft rejection (bronchiolitis obliterans syndrome) remains to be elucidated.

193 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin gr

194 al RNA (HCV RNA), freedom from bronchiolitis obliterans syndrome, acute rejection, and survival.

195 factor for the development of bronchiolitis obliterans syndrome, an important cause of late mortalit

196 , renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.

197 months, bacterial infections, bronchiolitis obliterans syndrome, and survival.

198 five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatment improved fo

199 limited by chronic rejection (bronchiolitis obliterans syndrome, BOS).

200 rophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled trial is awaited.

201 ion is a major risk factor for bronchiolitis obliterans syndrome, but noninvasive biomarkers have not

202 graft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term su

203 ses and in the pathogenesis of bronchiolitis obliterans syndrome, the predominant manifestation of ch

204 licated in the pathogenesis of bronchiolitis obliterans syndrome, which is considered to represent ch

205 g lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clinical and histo

206 ality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

207 ate the in vivo development of bronchiolitis obliterans syndrome-like lesions and reveal its sensitiv

208 iopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

209 g allograft rejection known as bronchiolitis obliterans syndrome.

210 tudy subjects remain free from bronchiolitis obliterans syndrome.

211 f primary graft dysfunction on bronchiolitis obliterans syndrome.

212 factor for the development of bronchiolitis obliterans syndrome.

213 served in the overall onset of bronchiolitis obliterans syndrome.

214 limited by the development of bronchiolitis obliterans syndrome.

215 lung function in patients with bronchiolitis obliterans syndrome.

216 factor for the development of bronchiolitis obliterans syndrome.

217 n linked to the development of bronchiolitis obliterans syndrome.

218 te rejection (AR) or developed bronchiolitis obliterans syndrome.

219 n increased risk of developing bronchiolitis obliterans syndrome.

220 idence of post-lung transplant bronchiolitis obliterans syndrome.

221 l to mesenchymal transition in bronchiolitis obliterans syndrome.

222 lung transplantation (LTX) is bronchiolitis obliterans syndrome.

223 patients prior to diagnosis of bronchiolitis obliterans syndrome.

224 acute cellular rejection, and bronchiolitis obliterans syndrome; however, the significance of circul

225 injury via TGF-beta in murine bronchiolitis obliterans; that TGF-beta and the C' cascade present sig

226 rease the chance of developing bronchiolitis obliterans; therefore, many centers perform surveillance

227 overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overall incidence of

228 onic illness in which meningeal endarteritis obliterans was consistently observed.

229 factors for the development of bronchiolitis obliterans were age older than 3 years, more than two ep

230 associated lymphoid tissue and bronchiolitis obliterans were unique for the immunizing virus, LCMV.

231 onsclerodermatous disease with bronchiolitis obliterans where cGVHD is dependent on antibody and germ

232 he major late complication was bronchiolitis obliterans, which occurred in 27% of patients and played

233 Bronchiolitis obliterans with organizing pneumonia (BOOP) was the most

234 athy and pulmonary findings of bronchiolitis obliterans with organizing pneumonia (BOOP).